journal

Lancet Neurology

journal
https://read.qxmd.com/read/32192575/social-media-could-address-the-gender-gap-in-neurosurgery
#1
LETTER
Emma Jane Norton, Soham Bandyopadhyay, Jigishaa Moudgil-Joshi
No abstract text is available yet for this article.
March 16, 2020: Lancet Neurology
https://read.qxmd.com/read/32171387/initiation-of-pharmacological-therapy-in-parkinson-s-disease-when-why-and-how
#2
REVIEW
Rob M A de Bie, Carl E Clarke, Alberto J Espay, Susan H Fox, Anthony E Lang
Debate is ongoing regarding when, why, and how to initiate pharmacotherapy for Parkinson's disease. Early initiation of dopaminergic therapies does not convey disease-modifying effects but does reduce disability. Concerns about the development of motor complications arising from the early initiation of levodopa, which led to misconceived levodopa-sparing strategies, have been largely mitigated by the outcomes of the PD MED and Levodopa in Early Parkinson's Disease (LEAP) studies. The LEAP study also showed the potential for early improvement in quality of life, even when disability is negligible...
March 12, 2020: Lancet Neurology
https://read.qxmd.com/read/32171386/a-pragmatic-personalised-approach-to-treatment-initiation-in-parkinson-s-disease
#3
Anthony Schapira
No abstract text is available yet for this article.
March 12, 2020: Lancet Neurology
https://read.qxmd.com/read/32169157/parkinson-s-disease-in-the-menasa-countries
#4
Hanan Khalil, Lana Chahine, Junaid Siddiqui, Zakiyah Aldaajani, Jawad A Bajwa
No abstract text is available yet for this article.
March 6, 2020: Lancet Neurology
https://read.qxmd.com/read/32142628/evidence-based-support-for-autistic-people-across-the-lifespan-maximising-potential-minimising-barriers-and-optimising-the-person-environment-fit
#5
REVIEW
Meng-Chuan Lai, Evdokia Anagnostou, Max Wiznitzer, Carrie Allison, Simon Baron-Cohen
Autism is both a medical condition that gives rise to disability and an example of human variation that is characterised by neurological and cognitive differences. The goal of evidence-based intervention and support is to alleviate distress, improve adaptation, and promote wellbeing. Support should be collaborative, with autistic individuals, families, and service providers taking a shared decision-making approach to maximise the individual's potential, minimise barriers, and optimise the person-environment fit...
March 3, 2020: Lancet Neurology
https://read.qxmd.com/read/32142627/setting-the-research-agenda-to-secure-the-wellbeing-of-autistic-people
#6
Kristelle Hudry, Elizabeth Pellicano, Mirko Uljarević, Andrew J O Whitehouse
No abstract text is available yet for this article.
March 3, 2020: Lancet Neurology
https://read.qxmd.com/read/32109411/30-years-of-second-generation-antiseizure-medications-impact-and-future-perspectives
#7
REVIEW
Emilio Perucca, Martin J Brodie, Patrick Kwan, Torbjörn Tomson
Since 1989, 18 second-generation antiseizure medications have reached the market, resulting in a greatly increased range of treatment options for patients and prescribers. 30 years have passed and now is the time for an appraisal of the effect of these medications on clinical outcomes. Every antiseizure medication needs to be assessed individually, but overall second-generation drugs are less likely to cause pharmacokinetic interactions than their older counterparts. Some second-generation antiseizure medications have shown advantages in tolerability and safety, particularly in the treatment of older patients and women of childbearing potential...
February 25, 2020: Lancet Neurology
https://read.qxmd.com/read/32109410/have-new-antiseizure-medications-improved-clinical-care-over-the-past-30-years
#8
Jacqueline A French, Robert T Wechsler
No abstract text is available yet for this article.
February 25, 2020: Lancet Neurology
https://read.qxmd.com/read/32059811/long-term-unsupervised-mobility-assessment-in-movement-disorders
#9
REVIEW
Elke Warmerdam, Jeffrey M Hausdorff, Arash Atrsaei, Yuhan Zhou, Anat Mirelman, Kamiar Aminian, Alberto J Espay, Clint Hansen, Luc J W Evers, Andreas Keller, Claudine Lamoth, Andrea Pilotto, Lynn Rochester, Gerhard Schmidt, Bastiaan R Bloem, Walter Maetzler
Mobile health technologies (wearable, portable, body-fixed sensors, or domestic-integrated devices) that quantify mobility in unsupervised, daily living environments are emerging as complementary clinical assessments. Data collected in these ecologically valid, patient-relevant settings can overcome limitations of conventional clinical assessments, as they capture fluctuating and rare events. These data could support clinical decision making and could also serve as outcomes in clinical trials. However, studies that directly compared assessments made in unsupervised and supervised (eg, in the laboratory or hospital) settings point to large disparities, even in the same parameters of mobility...
February 11, 2020: Lancet Neurology
https://read.qxmd.com/read/32059810/wearable-based-mobility-monitoring-the-long-road-ahead
#10
Alfonso Fasano, Martina Mancini
No abstract text is available yet for this article.
February 11, 2020: Lancet Neurology
https://read.qxmd.com/read/32059809/advances-in-oral-immunomodulating-therapies-in-relapsing-multiple-sclerosis
#11
REVIEW
Tobias Derfuss, Matthias Mehling, Athina Papadopoulou, Amit Bar-Or, Jeffrey A Cohen, Ludwig Kappos
BACKGROUND: Oral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action. These distinct mechanisms of action allow better adaption of treatments according to individual comorbidities and offer different mechanisms of treatment such as inhibition of immune cell trafficking versus immune cell depletion, thereby substantially expanding the available treatment options...
February 11, 2020: Lancet Neurology
https://read.qxmd.com/read/32057303/associations-of-paediatric-demyelinating-and-encephalitic-syndromes-with-myelin-oligodendrocyte-glycoprotein-antibodies-a-multicentre-observational-study
#12
Thaís Armangue, Gemma Olivé-Cirera, Eugenia Martínez-Hernandez, Maria Sepulveda, Raquel Ruiz-Garcia, Marta Muñoz-Batista, Helena Ariño, Veronica González-Álvarez, Ana Felipe-Rucián, Maria Jesús Martínez-González, Veronica Cantarín-Extremera, Maria Concepción Miranda-Herrero, Lorena Monge-Galindo, Miguel Tomás-Vila, Elena Miravet, Ignacio Málaga, Georgina Arrambide, Cristina Auger, Mar Tintoré, Xavier Montalban, Adeline Vanderver, Francesc Graus, Albert Saiz, Josep Dalmau
BACKGROUND: Investigations of myelin oligodendrocyte glycoprotein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG antibody-associated syndromes in children is unknown. In this study, we aimed to determine the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibodies, their response to treatment, and the phenotypes associated with poor prognosis. METHODS: In this prospective observational study, children with demyelinating syndromes and with encephalitis other than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres in Spain were investigated for MOG antibodies...
February 7, 2020: Lancet Neurology
https://read.qxmd.com/read/32057302/breaking-boundaries-between-demyelinating-disorders-and-autoimmune-encephalitis
#13
Romain Marignier
No abstract text is available yet for this article.
February 7, 2020: Lancet Neurology
https://read.qxmd.com/read/32004440/advances-and-challenges-in-stroke-rehabilitation
#14
REVIEW
Cathy M Stinear, Catherine E Lang, Steven Zeiler, Winston D Byblow
Stroke remains a leading cause of adult disability and the demand for stroke rehabilitation services is growing. Substantial advances are yet to be made in stroke rehabilitation practice to meet this demand and improve patient outcomes relative to current care. Several large intervention trials targeting motor recovery report that participants' motor performance improved, but to a similar extent for both the intervention and control groups in most trials. These neutral results might reflect an absence of additional benefit from the tested interventions or the many challenges of designing and doing large stroke rehabilitation trials...
January 28, 2020: Lancet Neurology
https://read.qxmd.com/read/31999942/%C3%AE-adrenoreceptors-and-the-risk-of-parkinson-s-disease
#15
REVIEW
Franziska Hopfner, Günter U Höglinger, Gregor Kuhlenbäumer, Anton Pottegård, Mette Wod, Kaare Christensen, Caroline M Tanner, Günther Deuschl
BACKGROUND: β-adrenoceptors are widely expressed in different human organs, mediate important body functions and are targeted by medications for various diseases (such as coronary heart disease and heart attack) and many β-adrenoceptor acting drugs are listed on the WHO Model List of Essential Medicines. β-adrenoceptor antagonists are used by billions of patients with neurological disorders, primarily for the treatment of migraine and action tremor (mainly essential tremor), worldwide...
January 27, 2020: Lancet Neurology
https://read.qxmd.com/read/31986256/interpretation-of-risk-loci-from-genome-wide-association-studies-of-alzheimer-s-disease
#16
REVIEW
Shea J Andrews, Brian Fulton-Howard, Alison Goate
BACKGROUND: Alzheimer's disease is a debilitating and highly heritable neurological condition. As such, genetic studies have sought to understand the genetic architecture of Alzheimer's disease since the 1990s, with successively larger genome-wide association studies (GWAS) and meta-analyses. These studies started with a small sample size of 1086 individuals in 2007, which was able to identify only the APOE locus. In 2013, the International Genomics of Alzheimer's Project (IGAP) did a meta-analysis of all existing GWAS using data from 74 046 individuals, which stood as the largest Alzheimer's disease GWAS until 2018...
January 24, 2020: Lancet Neurology
https://read.qxmd.com/read/31981516/efficacy-of-three-neuroprotective-drugs-in-secondary-progressive-multiple-sclerosis-ms-smart-a-phase-2b-multiarm-double-blind-randomised-placebo-controlled-trial
#17
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Gavin Giovannoni, Claudia Angela Gandini Wheeler-Kingshott, Clive Hawkins, Basil Sharrack, Roger Bastow, Christopher J Weir, Nigel Stallard, Siddharthan Chandran
BACKGROUND: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource. METHODS: We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 clinical neuroscience centres in the UK...
January 22, 2020: Lancet Neurology
https://read.qxmd.com/read/31981515/feast-or-famine-in-multiple-sclerosis-therapeutics
#18
Robert J Fox
No abstract text is available yet for this article.
January 22, 2020: Lancet Neurology
https://read.qxmd.com/read/31958406/the-characterisation-of-subjective-cognitive-decline
#19
REVIEW
Frank Jessen, Rebecca E Amariglio, Rachel F Buckley, Wiesje M van der Flier, Ying Han, José Luis Molinuevo, Laura Rabin, Dorene M Rentz, Octavio Rodriguez-Gomez, Andrew J Saykin, Sietske A M Sikkes, Colette M Smart, Steffen Wolfsgruber, Michael Wagner
A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline...
January 17, 2020: Lancet Neurology
https://read.qxmd.com/read/32199100/correction-to-lancet-neurol-2020-19-247-54
#20
(no author information available yet)
No abstract text is available yet for this article.
April 2020: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"